Indole compounds against breast cancer: recent developments.

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Breast cancer remains a leading cause of cancer mortality in women globally.
• Effective therapeutic strategies are continuously sought to improve patient outcomes.
• Indole derivatives represent a promising class of low-molecular-weight drugs for breast cancer treatment.

Purpose of the Study:

• To review recent advancements in indole-based drugs for breast cancer therapy.
• To highlight indole derivatives sourced from natural products.
• To detail the targets and mechanisms of action for these compounds.

Main Methods:

• Literature review of scientific publications from 2007 to 2012.
• Focus on indole derivatives, including 3,3'-diindolylmethane (DIM).
• Analysis of antimitotic vinca alkaloids and synthetic receptor tyrosine kinase inhibitors like sunitinib.

Main Results:

• Indole derivatives show significant efficacy in preclinical and clinical breast cancer studies.
• Natural product-derived indoles exhibit diverse mechanisms, including targeting specific cellular pathways.
• Key compounds like DIM and sunitinib demonstrate potent anti-cancer activity.

Conclusions:

• Indole-based compounds, particularly those from natural sources, offer a viable therapeutic avenue for breast cancer.
• Understanding the molecular targets and action modes is crucial for developing novel indole-based drugs.
• Further research into indole derivatives holds promise for improved breast cancer control and treatment.